FindTrial
Sign In

Expression of PD-L1, HER2/neu and CD 8 markers in endometrial cancer and its link to clinical and pathological features

Expression of PDL1, HER2/neu and CD8 in Endometrial carcinoma and its association with clinicopathological parameters - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/02/081069
Enrollment
30
Registered
2025-02-21
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C541- Malignant neoplasm of endometrium

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Maulana Azad Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients suspected with endometrial Cancer above 18 years of age will be selected from department of Obstetric and Gynaecology of Lok Nayak hospital diagnosed with endometrial carcinoma

Exclusion criteria

Exclusion criteria: All patients who have already received chemotherapy and radiotherapy will be excluded from study.

Design outcomes

Primary

MeasureTime frame
To study the mean expression of PDL1, Her 2/neu and CD-8 on endometrial carcinomaTimepoint: Baseline—

Secondary

MeasureTime frame
To study the association of PDL1, Her2/neu and CD-8 with clinicopathological parameters with grade, myometrial invasion, lymphovascular invasion and FIGO stageTimepoint: Baseline—

Countries

India

Contacts

Public ContactDr Vaishanvi

Maulana Azad Medical College, New Delhi

shra_mana@hotmail.com9811686401

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026